SLC26A4 has been identified as a potential alternative therapeutic target for asthma exacerbations, and inhibition of SLC26A4 has been considered a validated approach to increase airway surface liquid volume, and attenuate airway hyperresponsiveness in asthma [8,48,73]. This evidence concerns the gene SLC26A4 and airway hyperresponsiveness.